FDA recall D-0215-2026

Breckenridge Pharmaceutical, Inc. · Class II · drug

Product

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10.

Reason for recall

CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Distribution

Nationwide within the United States

Key facts

Status
Ongoing
Initiation date
2025-11-24
Report date
2025-12-10
Voluntary/Mandated
Voluntary: Firm initiated
Location
Berkeley Heights, NJ, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0215-2026